Elanco's Justine Conway Appointed as Board Observer of Neurizon Therapeutics

Neurizon® Therapeutics Limited, a clinical-stage biotech company focused on pioneering treatments for neurodegenerative diseases, has recently announced the strategic appointment of Ms. Justine Conway as a Board Observer. Ms. Conway, who holds the position of Global Head of Business Development at Elanco Animal Health, will represent Elanco in Neurizon's Board activities.

This significant development underscores the robust relationship between Neurizon and Elanco, as well as the latter's commitment to actively supporting Neurizon's growth. The appointment follows a global license agreement for Monepantel, integral to the development of Neurizon's leading candidate, NUZ-001, which aims to address Amyotrophic Lateral Sclerosis (ALS), one of the most common forms of motor neuron disease.

By integrating Elanco’s resources and insights, Neurizon is poised to enhance its regulatory foundation. Access to crucial animal safety data and manufacturing details will bolster the company's preparation for upcoming clinical trials, potential regulatory submissions, and eventual global market entry.

Ms. Conway's extensive background in both the animal health and healthcare sectors spans over two decades. Since joining Elanco in 2020, she has leveraged her investment banking expertise from Macquarie Bank and Bank of America Merrill Lynch to drive strategic initiatives and major business developments. Her vast experience includes leading numerous mergers and acquisitions transactions, making her an invaluable asset to Neurizon's governance.

As a Board Observer, Conway will have the opportunity to attend all Board and committee meetings, contributing to discussions without possessing voting rights. Neurizon's management is optimistic that her profound industry knowledge and strategic understanding will facilitate the advancement of NUZ-001 towards late-stage development and commercial readiness, alongside its planned entry into the HEALEY ALS Platform Trial in the upcoming quarter.

Mr. Sergio Duchini, Non-Executive Chairman of Neurizon, commented on Conway's appointment, expressing that her expertise strengthens an already productive partnership with Elanco. He stated, “Justine’s background in business development and strategic partnering will be invaluable as we advance our drug candidate towards regulatory submission and aim for commercialisation.”

With this collaboration, Neurizon aims not only to fast-track access to effective treatments for ALS but also to explore broader neurodegenerative applications for NUZ-001. As a dedicated entity in advancing complex neural disorder treatments, Neurizon’s commitment to its mission remains unwavering.

About Neurizon Therapeutics Limited:
Neurizon Therapeutics Limited is a biotechnology firm committed to developing innovative solutions for neurodegenerative diseases. Focusing on the clinical development of NUZ-001 for ALS, the company strives to create new possibilities for patients facing complex neural disorders and their families. This investigational drug is currently not approved for commercial use anywhere.